Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma

Inclusion Criteria: * Male or female patients \> 18 years and ≤ 70 years of age. * Diagnosis of pCCA or HCC (through imaging, serology, and/or histological biopsy) * Performance status: Karnofsky score ≥ 70 * Candidates for right portal vein embolization for potential major hepatectomy with curative intent. Volumetric indication for PVE is less than 40% of standardized FLR. * Selective biliary drainage on FLR side for patients with pCCA should be performed when total bilirubin level is above 85.5μmol/L or bile duct dilation of FLR presents. Transcatheter arterial chemoembolization should be performed between 1 and 4 weeks before PVE for patients with HCC. * Criteria of liver function: Child-Pugh A-B7 level, serum total bilirubin \< 85.5μmol/L after biliary drainage in pCCA, alanine aminotransferase and aspartate aminotransferase ≤ 3 times the upper limit of normal value. * Patients who can understand this trial and have signed the informed consent. Exclusion Criteria: * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment. * Patients with a history of any other malignant tumor, or allergic to iodine or gelatin. * Subjects participating in other clinical trials. * Platelet count \< 80×109/L and/or moderate or severe esophageal varices. * ICGR15 ≥ 15% for HCC patients * Obstructive jaundice lasts for \>2 months before PVE for pCCA patients. * Tumor becomes unresectable by local progression and/or distant metastasis present…